In patients with advanced NSCLC and PD‐L1 expression on at least 50% of tumour cells, pembrolizumab results in significantly longer PFS and OS [4], and thus, the determination of PD‐L1 expression in tissue samples is the reference factor for the selection of ICI treatments. This evidence concerns the gene CD274 and neoplasm.